Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11228378rdf:typepubmed:Citationlld:pubmed
pubmed-article:11228378lifeskim:mentionsumls-concept:C0020971lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0014834lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0074448lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0008356lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0028429lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0475463lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C1518413lld:lifeskim
pubmed-article:11228378lifeskim:mentionsumls-concept:C1711351lld:lifeskim
pubmed-article:11228378pubmed:issue15-16lld:pubmed
pubmed-article:11228378pubmed:dateCreated2001-3-6lld:pubmed
pubmed-article:11228378pubmed:abstractTextEscherichia coli O157:H7 produces two forms of verotoxin (VT), VT1 and VT2, which cause hemorrhagic colitis with development, in some cases, of hemolytic uremic syndrome. These toxins consist of an enzymatically active A subunit and pentamers of B subunit responsible for their binding to host cells. We used the secretion-expression system of Bacillus brevis to produce recombinant VT1B and VT2B. The secreted B subunits were purified and sequenced to verify their structure. Receptor-binding showed that rVT1B but not rVT2B bound to Gb3-receptor. When mice were nasally immunized with rVT1B or rVT2B together with a nontoxic mutant of cholera toxin (mCT) or native cholera toxin (nCT) as adjuvants, serum IgG and mucosal IgA antibody responses to VT1B were induced. The VT1B-specific antibodies prevented VT1B binding to its Gb3 receptor. In contrast, poor serum and no mucosal VT2B-specific antibodies but brisk CTB-specific antibody responses were induced by nasal immunization with rVT2B in the presence of mCT or nCT. These results show that nasal immunization with rVTB and mCT as a nontoxic mucosal adjuvant is an effective regimen for the induction of VT1B but not VT2B antibody responses which inhibit VT1B binding to Gb3 receptor.lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:languageenglld:pubmed
pubmed-article:11228378pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:citationSubsetIMlld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11228378pubmed:statusMEDLINElld:pubmed
pubmed-article:11228378pubmed:monthFeblld:pubmed
pubmed-article:11228378pubmed:issn0264-410Xlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:YamamotoSSlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:TakedaYYlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:McGheeJ RJRlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:KiyonoHHlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:KohsakaTTlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:YukiYYlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:FujihashiKKlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:UdakaSSlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:OhmuraMMlld:pubmed
pubmed-article:11228378pubmed:authorpubmed-author:ByunYYlld:pubmed
pubmed-article:11228378pubmed:issnTypePrintlld:pubmed
pubmed-article:11228378pubmed:day28lld:pubmed
pubmed-article:11228378pubmed:volume19lld:pubmed
pubmed-article:11228378pubmed:ownerNLMlld:pubmed
pubmed-article:11228378pubmed:authorsCompleteYlld:pubmed
pubmed-article:11228378pubmed:pagination2061-70lld:pubmed
pubmed-article:11228378pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:meshHeadingpubmed-meshheading:11228378...lld:pubmed
pubmed-article:11228378pubmed:year2001lld:pubmed
pubmed-article:11228378pubmed:articleTitleNasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.lld:pubmed
pubmed-article:11228378pubmed:affiliationJCR Biopharmaceuticals Incorporated, , San Diego, CA 92121-1194, USA.lld:pubmed
pubmed-article:11228378pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11228378pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11228378pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11228378lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11228378lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11228378lld:pubmed